Kirn David: insider trades.
Kirn David reported 9 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($3.0M), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 8
- Companies
- 1
- Name as filed
- Kirn David
Companies
| Company | Relationship | Transactions |
|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | Director, Officer · See Remarks | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-14 | 4D Molecular Therapeutics, Inc. | S | 58,333 | $13.9 | 767,486 | Form 4 |
| 2026-08-19 | 4D Molecular Therapeutics, Inc. | S | 43,149 | $15.36 | 851,746 | Form 4 |
| 2026-08-19 | 4D Molecular Therapeutics, Inc. | S | 25,927 | $16.42 | 825,819 | Form 4 |
| 2026-08-19 | 4D Molecular Therapeutics, Inc. | M | 50,000 | $4.14 | 894,895 | Form 4 |
| 2026-08-04 | 4D Molecular Therapeutics, Inc. | S | 26,842 | $10.23 | 844,895 | Form 4 |
| 2026-08-03 | 4D Molecular Therapeutics, Inc. | S | 12,415 | $10.05 | 871,737 | Form 4 |
| 2026-07-10 | 4D Molecular Therapeutics, Inc. | S | 15,283 | $12.01 | 884,594 | Form 4 |
| 2026-07-10 | 4D Molecular Therapeutics, Inc. | S | 442 | $12.84 | 884,152 | Form 4 |
| 2026-07-09 | 4D Molecular Therapeutics, Inc. | S | 42,608 | $12.87 | 899,877 | Form 4 |
Questions
What stock did Kirn David buy or sell?
Kirn David reported 9 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($3.0M), across 1 company.
Is Kirn David the same person as other filers with this name?
This page covers SEC CIK 1834021 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/kirn-david-1834021.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.